{
    "id": 29581,
    "fullName": "RPS6 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RPS6 over exp indicates an over expression of the Rps6 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6194,
        "geneSymbol": "RPS6",
        "terms": [
            "RPS6",
            "S6"
        ]
    },
    "variant": "over exp",
    "createDate": "03/21/2019",
    "updateDate": "03/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16500,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 did not respond to treatment with Saracatinib (AZD0530) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated only a minimal decrease in viability when treated with Pimasertib (MSC1936369B) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16498,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated resistance to treatment with Herceptin (trastuzumab) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16505,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of GSK2126458 and Tykerb (lapatinib) in ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated reduced cell viability in culture and decreased tumor growth and expression of Rps6 and Nfe2l2 in cell line xenograft models (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 8070,
                "therapyName": "GSK2126458 + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16496,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated resistance in both culture and cell line xenograft models when treated with Tykerb (lapatinib) (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-amplified gastric cancer cells overexpressing Nfe2l2 and Rps6 demonstrated non-significant reduced viability when treated with Afinitor (everolimus) in culture (PMID: 30504425).",
            "molecularProfile": {
                "id": 31652,
                "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14570,
                    "pubMedId": 30504425,
                    "title": "NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30504425"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31651,
            "profileName": "RPS6 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31652,
            "profileName": "ERBB2 amp NFE2L2 over exp RPS6 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}